4C was good and supports price continuing to rise.Operating Cash burn only $12.5m - lower than SI had indicated as we build up to $20m per quarter. Costs of capital raise less than $5m as I had hoped.Big news that the Type B meeting for AA will be held this quarter - should be before the end of May based on FDA guidelines. Many people had said cuts to FDA would affect drugs approvals, but this has not happened. There was also a risk that FDA might have refused the meeting request but that didn’t happen. Combined with Meso’s commentary about what FDA said in the Part B meeting for heart last year, and the approval already achieved for Ryoncil plus everything learned from that approval, this gives me increasing confidence that we stand a good chance of AA for heart, which would be a blockbuster and that sales could start by July 2026 based on SI guidance that à BLA could be lodged by the end of this year.That is probably a year or two before we could’ve expected. With valuation rates of 20-30% stepping up sales for blockbuster heart implies a big increase in the valuation, and we could get an announcement on this point n early June if the meeting goes very well, or maybe late June if we have to wait for FDA minutes.Ryoncil sales and back pain trial progress in line with expectations.All the recent fears that the shorts were spreading were wrong and we should trade back up to where we were before these fears about FDA, insurance, tariffs, etc hit the priceIt’s happening people!
Cool.
Aloha.
MSB Price at posting:
$1.80 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)